Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio - PubMed
3 hours ago
- #Biomarker Variability
- #Alzheimer's Disease
- #FDA-Cleared Tests
- The study evaluates the FDA-cleared Lumipulse P-Tau217/β-Amyloid 1-42 plasma ratio cut points for detecting Alzheimer's disease-related amyloid pathology.
- It is a cross-sectional investigation into the clinical performance variability of this blood-based biomarker test.
- The focus is on assessing how effectively the established ratio thresholds identify amyloid pathology in a clinical setting.